| INTRODUCTION
An unmet need for metastatic resistant prostate cancer (mCRPC) is development of effective therapy eradicating tumors. Despite advances in drug development resistance emerges. 1 Generally there are two possibilities how resistance emerges in a tumor: (i) during drug treatment the tumor mutates and becomes resistance due to genomic instability (acquired resistance) or (ii) prior to treatment there are already pre-existing clones that are resistant (innate resistance). When treatment commences these pre-existing clones thrive due to their drug resistance (increased fitness) under the selection pressure of the drugs. Due to the large number of cells per tumor (∼10 9 cells) it is likely that one or more clones already possess a resistance mechanism. Mechanistically, resistance in mCRPC can emerge due to androgen receptor (AR) splice variants, increased activation or expression of AR, co-activation of AR via non-hormonal
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
entities, activation of glucocorticoid receptor, increased drug efflux, and β-tubulin or cell growth pathways might be dysregulated. 2 Within a mCRPC patient multiple of these resistance mechanisms might be found due to the heterogeneity within large tumors and across multiple metastatic sites. 1, 3 Many resistance mechanisms manifest themselves on the genomic level due to genomic instability found within cancer cells. [4] [5] [6] Hence, identification of mechanisms of escape from treatment remain a priority. 7 Ultimately combination therapies targeting multiple escape mechanism will be developed as is already the case for HIV, TB, and some cancers. 8 In order to gauge the influence of genetic background, tumor heterogeneity, and drug potency on plausible eradication of mCRPC we used a computational simulation approach. In particular, we used theoretical evolutionary dynamics which provides insights into how prostate cancer evolves and evades resistance. 9 Here, we apply a recently developed stochastic branching process model 10 to estimate the probability that resistance will emerge to two-drug therapy.
| METHOD
To compute a probability of eradication, P erad , the model determines four independent events:
where P 1b is the probability that no 1-step resistant lineage arises before treatment, P 1t is the probability that no 1-step lineages arise during treatment, P 2b is the probability that no 2-step lineages arise before treatment, and P 2t is the probability that no 2-step lineages arise during treatment. Each is determined as follows:
where M is the number of cells in the tumor, u is the mutation rate, s = 1 
| Parameterization of equations
To parameterize model Equations 1-4 we used publicly available patient data that was carefully compiled by the cancer research community across multiple research studies, see Table 1 . Tumor sizes of mCRPC derive from radiography. 11 The number of tumor cells per cubic cm was obtained from Lutz et al. 12 Growth rates were obtained from median values reported by Wilkerson et al. from a meta-analysis using the median growth rate of resistant tumors (see Figure 3a and sensitive Figure 3b ). 13 There are approximately 50 known mechanisms of resistance to androgen deprivation therapy and approximately 50 mechanisms for other targeted inhibitors. 10 Point mutation rates were assumed to follow the typical value for human cancers of 1 × 10 For the worst case scenario, we assumed a single alteration conferring resistance to two-drug combination therapy, for example, increased drug efflux (scenario A). The probability of eradication is below 25% for tumors that are 10 8 cells (∼0.5 cm 3 volume or ∼0.5 cm radius). Another scenario concerns a very high mutation rate on the genomic level. In scenario B, there are no cross-resistance mutations, but a fourfold higher number of mutations capable of conferring resistance to each drug alone, that is, from 50 to 200. Similar to A, scenario B also predicts very poor probability for eradication (see Figure 1 ). Both results show that at the limit of detection for PET scan, the probability of eradicating the tumor is 50%. In the case of typical tumors (2-4 cm, 33 cm Figure 1) . However, for tumors with 10 9 cells (∼5 cm 3 or ∼1 cm radius) at the initiation of treatment, the probability of eradication is less than 50%. Even under this best case scenario constant monitoring and early detection of small tumors is key to eradicating tumors using a two-drug combination.
To investigate whether potency of the two-drug combination is critical to eradication, we changed the drug efficacy by an order of magnitude (scenarios D and E) leaving all other parameters as best case scenario C. Surprisingly, the 10-fold increase in drug potency had little effect on the probability of eradication given a certain tumor size (see Figure 1 ).
| DISCUSSION
Overall, this study finds that two-drug combinations are unlikely to be effective at overcoming the emergence of resistance in mCRPC. This is FIGURE 1 Probability of tumor eradication by two-drug combination therapy. On the x-axis the tumor size is plotted on a log 10 scale in cm 3 while on the y-axis the probability of eradiation is plotted. The two-drug simulation tested growth rate during drug treatment (s′), as well as mutations conferring resistance (n 1 and n 2 ) and cross-resistance (n 12 ). Typical metastatic tumors are 2-4 cm 3 in size and genetic background is critical for probability of eradication using two-drug combinations. [Color figure can be viewed at wileyonlinelibrary.com]
due to large initial tumor burden associated with the limit of detection for current Positron Emission Tomography (PET) scan technology. At the time a tumor is detectable by PET, tumors with unfavorable genetic background only have a 50% chance of tumor eradication. Advances in PET imaging technology, for example, digital PET, will undoubtedly shift the boundaries to earlier detection of tumors increasing the chance of tumor eradication using a two-drug combination.
Another contributing factor is tumor heterogeneity, where clones are present in the tumor at the start of therapy that are resistant to both drugs. Through selective pressure during pharmacological treatment these resistant clones will be selected due to their fitness. Additionally, by chance new mutations will arise in clones and evolve during treatment. In an examination of patient data, Hieronymus et al showed that the higher the total level of copy number variation (CNV) change the worse the patient's outcome. 15 This is in agreement with our calculations that indicate greater genomic instability increases the probability of disease progression.
A potential cause for inaccuracies of our evolutionary dynamics model is the estimation of mutation rate. Prostate cancer typically shows more CNV than mutations. For the purpose of our evolutionary dynamics model we rationalized that the number of DNA repair events is critical, but not the nature of the events.
Hence, we set a typical value for human cancers to reflect CNV and mutations. If the mutation rate increases due to genomic stability or is much greater than is typical for cancer used here, the simulations would conclude an even lower probability of eradication.
Additionally the number of single mutations that can confer crossresistance to two drugs are another confounding factor. In that worst case scenario there is an even lower probability of eradication. For example, if there are multiple drug transporters capable of conferring cross-resistance, then a copy number amplification of a single gene will confer cross-resistance and the parameter n 12 is greater than 1, perhaps as high as 10. This greatly diminishes the probability of eradication.
Despite significant experimental challenges, higher-order drug combinations consisting of more than two drugs should be pursued in preclinical models. Recent theoretical advances suggest that higher-order drug combinations may be predictable from a dose series of drug pairs. 16 This method potentially provides an efficient means of developing drug combinations from a large drug library. In a complementary approach, knowledge from sequencing prostate cancer and mechanistic preclinical studies will help assemble effective drug combinations drug-by-drug. 
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